Welcome to Paid Research Studies




  • Condition:   Renal Transplant Infection
    Interventions:   Drug: Study Group;   Drug: Control Group
    Sponsor:   University of Alabama at Birmingham
    Not yet recruiting

  • Condition:   Transplant;Failure,Kidney
    Intervention:   Drug: Tacrolimus
    Sponsors:   Sentara Norfolk General Hospital;   Veloxis Pharmaceuticals
    Not yet recruiting

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Myeloproliferative Disorder;   Chronic Lymphocytic Leukemia;   B-cell Lymphoma;   T-cell Lymphoma;   Non Hodgkin Lymphoma;   Hodgkin Lymphoma;   Chronic Myelomonocytic Leukemia
    Interventions:   Radiation: Total body irradiation (TBI);   Drug: Anti-thymocyte globulin (ATG);   Drug: Tacrolimus;   Drug: Mycophenolate mofetil (MMF);   Radiation: Total lymphoid irradiation (TLI)
    Sponsor:   Stanford University
    Recruiting

  • Condition:   Kidney Transplant
    Intervention:   Drug: Tacrolimus Extended Release Oral Tablet [Envarsus] 0.13mg/kg/day initiated within post-operative day 3 after kidney transplant
    Sponsors:   Temple University;   Veloxis Pharmaceuticals
    Recruiting

  • Conditions:   Kidney Transplant;   Renal Transplant Recipients
    Interventions:   Biological: DCreg: 0.5 million cells/kg+SOC;   Biological: DCreg: 1.2 million cells/kg+SOC;   Biological: DCreg:2.5 to 5.0 million cells/kg+SOC
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   University of Pittsburgh
    Not yet recruiting

  • Condition:   End Stage Renal Disease
    Interventions:   Drug: Envarsus;   Drug: Tacrolimus
    Sponsors:   University of Kansas Medical Center;   Veloxis Pharmaceuticals
    Recruiting

  • Condition:   Hematopoietic and Lymphoid Cell Neoplasm
    Interventions:   Radiation: Total-Body Irradiation;   Procedure: Donor Lymphocyte Infusion;   Drug: Cyclophosphamide;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   GVHD;   Hematologic Neoplasms
    Interventions:   Drug: Cyclophosphamide;   Drug: abatacept;   Drug: Methotrexate;   Drug: Tacrolimus
    Sponsors:   Dimitrios Tzachanis, MD PhD;   Bristol-Myers Squibb
    Not yet recruiting

  • Conditions:   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Chronic Myelomonocytic Leukemia;   Myeloproliferative Neoplasm, Unclassifiable
    Interventions:   Biological: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total-Body Irradiation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Bone Marrow Transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus;   Biological: Granulocyte Colony-Stimulating Factor
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Lymphoproliferative Disorders;   Autoimmune Lymphoproliferative;   Primary T-cell Immunodeficiency Disorders;   Immune System Diseases;   Common Variable Immunodeficiency
    Interventions:   Drug: Immunosuppression Only Conditioning (IOC);   Drug: Reduced Intensity Conditioning (RIC);   Drug: GVHD Prophylaxis;   Procedure: Allogeneic HSC
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Graft-versus-host-disease;   GVHD;   GVHD, Acute
    Interventions:   Drug: BMS-986004;   Drug: Sirolimus;   Drug: Tacrolimus
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Bristol-Myers Squibb
    Not yet recruiting

  • Conditions:   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Blasts 5 Percent or Less of Bone Marrow Nucleated Cells;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Donor;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Myelofibrosis;   Myeloproliferative Neoplasm;   Recurrent Acute Myeloid Leukemia;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Refractory Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia
    Interventions:   Biological: Anti-Thymocyte Globulin;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Drug: Methotrexate;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Condition:   Heart Transplant
    Interventions:   Biological: tocilizumab;   Biological: Placebo;   Drug: Standard of Care Triple IS
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  • Condition:   Liver Transplant
    Interventions:   Biological: arTreg;   Procedure: leukapheresis;   Drug: cyclophosphamide;   Drug: mesna;   Drug: everolimus
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN)
    Not yet recruiting

  • Condition:   Kidney Transplantation
    Intervention:   Drug: Belimumab
    Sponsors:   University of Wisconsin, Madison;   GlaxoSmithKline;   American College of Surgeons
    Recruiting

  • Condition:   Kidney Transplant; Complications
    Interventions:   Drug: Once daily immunosuppression regimen;   Drug: Twice daily immunosuppression regimen
    Sponsors:   Washington University School of Medicine;   Veloxis Pharmaceuticals
    Recruiting

  • Conditions:   Liver Transplant;   Kidney Transplant
    Interventions:   Other: PPM-based Computation Assisted Drug Dosing;   Drug: Tacrolimus
    Sponsors:   University of Florida;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting

  • Condition:   Liver Transplant
    Interventions:   Biological: arTreg-CSB;   Procedure: leukapheresis;   Drug: cyclophosphamide;   Drug: mesna;   Drug: everolimus
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN)
    Not yet recruiting

  • Conditions:   Renal Transplant Rejection;   Kidney Transplant Failure and Rejection
    Interventions:   Drug: Tacrolimus Extended Release Oral Tablet;   Drug: Tacrolimus
    Sponsors:   Columbia University;   Veloxis Pharmaceuticals
    Not yet recruiting

  • Conditions:   Severe Aplastic Anemia (SAA);   Hypo-Plastic Myelodysplastic Syndrome (MDS)
    Intervention:   Procedure: haplo-identical transplantation
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Idiopathic Pulmonary Fibrosis;   Emphysema or COPD
    Interventions:   Biological: CD3/CD19 negative hematopoietic stem cells;   Drug: Rituximab;   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Thiotepa;   Drug: G-CSF;   Drug: Hydroxyurea
    Sponsor:   Paul Szabolcs
    Recruiting

  • Conditions:   Kidney Transplant; Complications;   Toxicity;   Drug Toxicity;   Neurotoxicity
    Interventions:   Drug: Envarsus;   Drug: IR Tacrolimus
    Sponsors:   University of California, Davis;   Veloxis Pharmaceuticals
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Chronic Lymphocytic Leukemia;   Chronic Myeloid Leukemia;   Myelodysplasia;   Myeloproliferative Disorder;   Myelofibrosis;   Lymphoma;   Lymphoma, Non-Hodgkin;   Plasma Cell Disorder
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Radiation: Total Body Irradiation;   Drug: Tacrolimus;   Drug: cellcept;   Drug: g-csf;   Procedure: Peripheral Blood Transplant
    Sponsor:   Dartmouth-Hitchcock Medical Center
    Recruiting

  • Conditions:   Acute Myeloid Leukemia in Remission;   Hematopoietic Cell Transplantation Recipient
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Tacrolimus;   Radiation: Total Marrow Irradiation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Pediatric ALL
    Intervention:   Drug: Standard of care drug
    Sponsor:   Duke University
    Recruiting

  • Conditions:   Kidney Transplant; Complications;   Kidney Transplant Failure and Rejection
    Interventions:   Drug: Envarsus;   Drug: Tacrolimus
    Sponsors:   California Institute of Renal Research;   Balboa Institute of Transplantation;   University of California, San Diego
    Recruiting

  • Conditions:   Renal Transplantation;   Mesenchymal Stem Cells
    Interventions:   Biological: Mesenchymal Stromal Stem Cells (MSCs) Infusion;   Other: Normal Saline (Placebo) Infusion
    Sponsors:   Ahmed Osama Gaber, MD;   The Methodist Hospital System;   Center for Cell and Gene Therapy, Baylor College of Medicine
    Recruiting

  • Condition:   Kidney Transplant; Complications
    Intervention:   Drug: Tacrolimus, Extended Release, (Envarsus Xr)
    Sponsor:   Yale University
    Recruiting

  • Condition:   End Stage Liver Disease
    Interventions:   Drug: Tacrolimus;   Drug: Everolimus
    Sponsors:   University of Kansas Medical Center;   Novartis Pharmaceuticals
    Recruiting

  • Condition:   Myelofibrosis
    Interventions:   Drug: Melphalan;   Drug: Fludarabine;   Radiation: Total Body Irradiation (TBI);   Procedure: Stem Cell Infusion;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Drug: G-CSF
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Condition:   Post Liver Transplant
    Interventions:   Drug: EnvarsusXR;   Drug: Tacrolimus
    Sponsors:   Albert Einstein Healthcare Network;   Veloxis Pharmaceuticals
    Recruiting

  • Conditions:   Lung Transplant Rejection;   Antibody-mediated Rejection
    Interventions:   Drug: Belatacept;   Drug: Tacrolimus;   Drug: ATG;   Drug: Mycophenolate Mofetil;   Drug: Methylprednisolone;   Drug: Prednisone
    Sponsors:   Ramsey Hachem;   National Heart, Lung, and Blood Institute (NHLBI);   Bristol-Myers Squibb
    Not yet recruiting

  • Condition:   Kidney Transplant Rejection
    Interventions:   Drug: Tacrolimus Extended Release Oral Tablet [Envarsus];   Other: Plasma Exchange and IVIG (Intravenous Immunoglobulin )
    Sponsors:   University of Colorado, Denver;   Veloxis Pharmaceuticals
    Recruiting

  • Conditions:   Heart Transplant Rejection;   Graft Failure;   Compliance, Patient
    Intervention:   Drug: Envarsus
    Sponsor:   Baylor Research Institute
    Recruiting

  • Conditions:   Pediatric Heart Transplantation;   Immunosuppression;   Chronic Kidney Diseases;   Cardiac Allograft Vasculopathy;   Heart Transplant Failure and Rejection;   Post-transplant Lymphoproliferative Disorder;   Heart Transplant Infection
    Interventions:   Drug: Everolimus;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil
    Sponsors:   Boston Children’s Hospital;   Stanford University;   United States Department of Defense
    Recruiting

  • Condition:   End Stage Renal Disease
    Interventions:   Drug: Tacrolimus;   Drug: Envarsus XR
    Sponsors:   Roberto Gedaly;   Veloxis Pharmaceuticals
    Recruiting

  • Conditions:   End Stage Renal Disease;   Rejection of Renal Transplant
    Interventions:   Drug: Tacrolimus;   Drug: Tacrolimus Extended Release Oral Tablet [Envarsus]
    Sponsor:   Lorenzo Gallon
    Recruiting

  • Conditions:   Acute Leukemia;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Lymphoma;   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myeloproliferative Neoplasms;   Myelofibrosis;   Myelodysplasia;   Refractory Anemia;   High Risk Anemia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Diffuse Large Cell Non Hodgkins Lymphoma;   Lymphoblastic Lymphoma;   Burkitt Lymphoma;   High Grade Non-Hodgkin's Lymphoma, Adult;   Multiple Myeloma;   Juvenile Myelomonocytic Leukemia;   Biphenotypic/Undifferentiated/Prolymphocytic Leukemias;   MRD Positive Leukemia;   Natural Killer Cell Malignancies;   Acquired Bone Marrow Failure Syndromes
    Interventions:   Biological: HSCT with TBI Regimen;   Biological: HSCT with Non-TBI Regimen
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Renal Transplant Patients
    Intervention:   Drug: Envarsus XR
    Sponsor:   University of Colorado, Denver
    Recruiting

  • Conditions:   Kidney Transplantation;   Renal Transplantation;   Grafting, Kidney
    Interventions:   Drug: Envarsus XR;   Drug: Tacrolimus
    Sponsors:   Meghan Pearl, MD;   Veloxis Pharmaceuticals
    Not yet recruiting

  • Condition:   Disorder Related to Renal Transplantation
    Intervention:   Drug: Tacrolimus XR (Envarsus)
    Sponsors:   University of Illinois at Chicago;   Veloxis Pharmaceuticals
    Recruiting

  • Condition:   Hematologic Malignancies
    Interventions:   Drug: Itacitinib;   Drug: Calcineurin inhibitor
    Sponsor:   Incyte Corporation
    Recruiting

  • Condition:   Immune Tolerance
    Interventions:   Procedure: Immune tolerance after kidney transplant;   Drug: Donor blood stem cells and T cells
    Sponsors:   Samuel Strober;   California Institute for Regenerative Medicine
    Recruiting

  • Conditions:   Sickle Cell Disease;   Sickle Cell Disorder;   Hemoglobinopathies;   Thalassemia;   Anemia, Sickle Cell
    Interventions:   Drug: Cyclophosphamide;   Drug: Pentostatin;   Drug: Rabbit anti-thymocyte globulin;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Biological: CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant
    Sponsors:   City of Hope Medical Center;   California Institute for Regenerative Medicine
    Recruiting

  • Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: Sorafenib;   Drug: Busulfan;   Drug: Fludarabine;   Procedure: Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Filgrastim;   Drug: Mycophenolate mofetil
    Sponsors:   M.D. Anderson Cancer Center;   Bayer
    Recruiting

  • Conditions:   Urologic Injuries;   Genital Diseases, Male;   Amputation
    Interventions:   Procedure: Penile Transplant;   Biological: Monoclonal Antibody (Humanized Anti-CD52);   Drug: Tacrolimus
    Sponsor:   Wake Forest University Health Sciences
    Recruiting

  • Conditions:   Hyperkalemia;   Kidney Transplant
    Intervention:   Drug: Patiromer
    Sponsors:   The Rogosin Institute;   Weill Medical College of Cornell University
    Recruiting

  • Condition:   End Stage Renal Disease
    Intervention:   Drug: Tacrolimus Extended Release Oral Capsule
    Sponsors:   Cedars-Sinai Medical Center;   Astellas Pharma Inc
    Recruiting

  • Conditions:   Acute Myeloid Leukemia in Remission;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission;   Chronic Myelomonocytic Leukemia in Remission;   Graft Versus Host Disease;   Hodgkin Lymphoma;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Plasma Cell Myeloma;   Severe Aplastic Anemia;   Waldenstrom Macroglobulinemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan Hydrochloride;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Age-Related Macular Degeneration
    Interventions:   Drug: ASP7317;   Other: Placebo;   Drug: tacrolimus;   Drug: mycophenolate mofetil (MMF)
    Sponsor:   Astellas Institute for Regenerative Medicine
    Recruiting

  • Conditions:   Acute Leukemia;   Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Diffuse Large B-Cell Lymphoma;   Follicular Lymphoma;   Graft Versus Host Disease;   Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   Secondary Myelodysplastic Syndrome
    Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Procedure: Hematopoietic Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan Hydrochloride;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Quality-of-Life Assessment;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes
    Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Drug: ATG;   Radiation: Total Marrow Irradiation;   Procedure: Stem Cell Product Infusion;   Drug: Tacrolimus;   Drug: Methotrexate
    Sponsor:   University of Illinois at Chicago
    Recruiting

  • Condition:   Secondary Myelofibrosis
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Glycosylated Recombinant Human G-CSF AVI-014;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Severe Sickle Cell Disease;   Bone Marrow Failure Syndromes;   Metabolic Disorders;   Immunologic Disorders;   Hemoglobinopathies;   Non-malignant Disorders
    Interventions:   Drug: RIC regimen;   Drug: GVHD prophylaxis regimen
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndrome;   Non-hodgkin Lymphoma;   Chronic Lymphocytic Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Other: Haploidentical Stem Cell Transplantation
    Sponsor:   Loyola University
    Recruiting

  • Condition:   Hematopoietic/Lymphoid Cancer
    Interventions:   Drug: Busulfan;   Drug: Rituximab;   Drug: ATG;   Drug: Fludarabine;   Drug: Clofarabine;   Radiation: Total Body Irradiation;   Procedure: Cord Blood Transplant;   Drug: Mycofenolate mofetil;   Drug: Tacrolimus;   Drug: Filgrastim-sndz;   Drug: Melphalan;   Drug: Cyclophosphamide;   Drug: Mesna
    Sponsors:   M.D. Anderson Cancer Center;   Mesoblast, Inc.
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   B-cell Non Hodgkin Lymphoma;   Pre B-Cell Acute Lymphoblastic Leukaemia
    Interventions:   Drug: Blinatumomab;   Drug: Dexamethasone
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Amgen
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: Atorvastatin;   Drug: Methotrexate;   Drug: Tacrolimus
    Sponsor:   Loyola University
    Recruiting

  • Condition:   Renal Transplant
    Intervention:   Drug: Tacrolimus
    Sponsor:   University of North Carolina, Chapel Hill
    Recruiting

  • Condition:   Hematopoietic and Lymphoid Cell Neoplasm
    Interventions:   Radiation: Total-Body Irradiation;   Procedure: Donor Lymphocyte Infusion;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Condition:   Ulcerative Colitis
    Interventions:   Drug: Tacrolimus;   Drug: Vedolizumab;   Other: Placebo
    Sponsors:   Medical College of Wisconsin;   Takeda
    Recruiting

  • Condition:   Renal Transplant Recipients
    Intervention:   Drug: ENVARSUS®
    Sponsor:   Georgetown University
    Recruiting

  • Condition:   Immunosuppression
    Interventions:   Drug: Tacrolimus;   Drug: Prednisone;   Drug: Mycophenolate mofetil;   Drug: Everolimus
    Sponsor:   Medical University of South Carolina
    Recruiting

  • Condition:   Hematologic Malignancies
    Interventions:   Biological: Haplo HCT <55 years old;   Biological: Haplo HCT ≥55 years old;   Drug: GVHD Prophylaxis
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Primary Myelofibrosis;   Secondary Myelofibrosis
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacological Study;   Drug: Ruxolitinib Phosphate;   Drug: Sirolimus;   Drug: Tacrolimus
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Graft Vs Host Disease;   GVHD
    Interventions:   Drug: Pacritinib;   Drug: Sirolimus;   Drug: Tacrolimus
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   CTI BioPharma
    Recruiting

  • Conditions:   Kidney Transplantation;   Focal Segmental Glomerulosclerosis (FSGS)
    Interventions:   Drug: Bleselumab;   Drug: Basiliximab;   Drug: Mycophenolate Mofetil (MMF);   Drug: Tacrolimus Capsules;   Drug: Methylprednisone;   Drug: Prednisone
    Sponsors:   Astellas Pharma Global Development, Inc.;   Kyowa Hakko Kirin Co., Ltd
    Recruiting

  • Condition:   Severe Aplastic Anemia
    Interventions:   Drug: Antithymocyte Globulin (ATG);   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation (TBI);   Procedure: Haplo HSCT;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil (MMF);   Drug: G-CSF
    Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network;   National Marrow Donor Program
    Recruiting

  • Condition:   Renal Transplant Rejection
    Interventions:   Drug: Prograf;   Drug: Tacrolimus
    Sponsors:   University of California, Los Angeles;   Food and Drug Administration (FDA)
    Recruiting

  • Condition:   Hematologic Malignancy
    Interventions:   Drug: melphalan;   Drug: fludarabine;   Drug: thiotepa;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Mycophenolate Mofetil;   Drug: Filgrastim;   Drug: Tacrolimus
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Other Diseases of Blood and Blood-forming Organs;   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myeloid Leukemia;   Chronic Lymphocytic Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Syndrome;   Non-Hodgkins Lymphoma;   Hodgkins Lymphoma;   Multiple Myeloma
    Interventions:   Drug: Busulfan;   Drug: Thiotepa;   Drug: Fludarabine monophosphate;   Procedure: Stem Cell Infusion;   Drug: Mesna;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Drug: G-CSF
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Sickle Cell Disease;   Graft Versus Host Disease
    Interventions:   Drug: Diphenhydramine;   Drug: Acetaminophen;   Drug: Methylprednisolone;   Drug: Meperidine;   Drug: Alemtuzumab;   Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Thiotepa;   Drug: Cyclosporine;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Abatacept;   Procedure: Marrow infusion;   Drug: Sirolimus;   Drug: Mycophenolate Mofetil
    Sponsor:   Monica Bhatia
    Recruiting

  • Conditions:   Severe Aplastic Anemia;   Aplastic Anemia;   Bone Marrow Failure;   Immunosuppression
    Interventions:   Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total body irradiation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Myeloid Sarcoma;   Chronic Myeloid Leukemia (CML);   Juvenile Myelomonocytic Leukemia (JMML);   Myelodysplastic Syndrome (MDS);   Non-Hodgkin Lymphoma (NHL)
    Interventions:   Drug: Anti-thymocyte globulin (rabbit);   Drug: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: G-CSF;   Drug: Melphalan;   Drug: Mesna;   Drug: Rituximab;   Drug: Tacrolimus;   Drug: Thiotepa;   Biological: HPC,A Infusion;   Device: CliniMACS;   Drug: Sirolimus
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Single dose total body irradiation;   Procedure: Graft cell infusion;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: G-CSF;   Procedure: CIML NK cell infusion;   Drug: ALT-803;   Procedure: Leukapheresis
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Condition:   Liver Transplantation
    Intervention:   Drug: Tacrolimus Withdrawal and Everolimus Monotherapy
    Sponsors:   Northwestern University;   Novartis Pharmaceuticals
    Recruiting

  • Condition:   Sickle Cell Disease
    Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: r-ATG;   Procedure: Bone Marrow Transplant;   Drug: Tacrolimus;   Drug: Methotrexate;   Procedure: Standard of Care
    Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   Dana-Farber Cancer Institute;   National Marrow Donor Program
    Recruiting

  • Condition:   Kidney Transplantation
    Interventions:   Drug: Tacrolimus;   Drug: Tacrolimus immediate release
    Sponsor:   Astellas Pharma Global Development, Inc.
    Recruiting

  • Conditions:   HIV Infections;   Kidney Diseases
    Interventions:   Drug: Maraviroc;   Drug: Placebo
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  • Conditions:   Kidney Transplant;   Adult Living Donor Kidney Transplant Recipients;   Renal Transplant;   Living Kidney Donor
    Interventions:   Biological: Polyclonal Regulatory T Cells;   Biological: Donor-Alloantigen-Reactive Regulatory T Cells;   Drug: Everolimus;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Mycophenolic acid;   Drug: Acetaminophen;   Drug: Diphenhydramine;   Procedure: Biopsy, Kidney;   Procedure: Blood Draw;   Procedure: Leukapheresis;   Procedure: IS regimen conversion
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Clinical Trials in Organ Transplantation
    Recruiting

  • Conditions:   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myelodysplastic Syndromes;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Non-Hodgkin's Lymphoma;   Multiple Myeloma;   Myeloproliferative Syndromes;   Hematological Diseases
    Interventions:   Drug: Allopurinol;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: ATG;   Radiation: TBI;   Drug: Tacrolimus;   Drug: MMF;   Biological: Peripheral Blood Stem Cells;   Biological: Related or Unrelated Bone Marrow Cells
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Epidermolysis Bullosa
    Interventions:   Drug: Thymoglobulin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Radiation: Total Body Irradiation;   Procedure: Bone marrow infusion;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Biological: Donor mesenchymal stem cell infusions
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia in Remission;   Aplastic Anemia;   Chronic Myelomonocytic Leukemia;   Hodgkin Lymphoma;   Indolent Non-Hodgkin Lymphoma;   Malignant Neoplasm;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Plasma Cell Myeloma;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ring Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
    Interventions:   Drug: Fludarabine;   Radiation: Total-Body Irradiation;   Biological: T Cell-Depleted Donor Lymphocyte Infusion;   Drug: Cyclophosphamide;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Condition:   Heart Failure
    Intervention:   Drug: tacrolimus extended release
    Sponsor:   Newark Beth Israel Medical Center
    Recruiting

  • Conditions:   Sarcoma;   Malignant Peripheral Nerve Sheath Tumors
    Interventions:   Drug: PLX3397;   Drug: Sirolimus
    Sponsors:   Gulam Manji;   Plexxikon
    Recruiting

  • Conditions:   Plasma Cell Leukemia;   Recurrent Plasma Cell Myeloma
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Ixazomib Citrate;   Drug: Melphalan;   Drug: Methotrexate;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Quality-of-Life Assessment;   Drug: Tacrolimus
    Sponsors:   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Kidney Transplant
    Interventions:   Biological: Infliximab;   Drug: Methylprednisolone;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Biological: Thymoglobulin;   Drug: Acetaminophen;   Drug: Loratadine;   Biological: Placebo for Infliximab;   Drug: Prednisone;   Drug: Diphenhydramine
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Clinical Trials in Organ Transplantation
    Recruiting

  • Condition:   Solid Tumor
    Interventions:   Drug: Bevacizumab;   Drug: Cyclophosphamide;   Drug: Valproic Acid;   Drug: Temsirolimus
    Sponsors:   Miller Children's & Women's Hospital Long Beach;   Children’s Hospital of Orange County
    Recruiting

  • Conditions:   Amputation;   Wounds and Injuries;   Amputation, Traumatic;   Urologic Surgical Procedures, Male;   Amputation, Traumatic/Surgery;   Penis/Transplantation;   Penis/Surgery;   Penis/Injuries
    Interventions:   Procedure: Penile Transplant;   Biological: Monoclonal Antibody (Humanized Anti-CD52);   Drug: Tacrolimus
    Sponsor:   Johns Hopkins University
    Recruiting

  • Condition:   Abdominal Wall Defect
    Interventions:   Procedure: abdominal wall transplantation;   Drug: Immunosuppressive Agents
    Sponsor:   Brigham and Women's Hospital
    Recruiting

  • Conditions:   Acute Leukemia;   Myelodysplasia
    Interventions:   Procedure: Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate;   Procedure: Mobilized CD34-selected Peripheral Blood Stem Cell graft;   Procedure: Unmanipulated Bone Marrow Graft with Cyclophosphamide;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Methotrexate
    Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Hematologic Malignancy
    Interventions:   Drug: Fludarabine Phosphate;   Drug: Melphalan;   Radiation: Intensity-Modulated Radiation Therapy;   Radiation: Total Marrow Irradiation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Allogeneic Bone Marrow Transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Other: Laboratory Biomarker Analysis
    Sponsors:   University of Chicago;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Myelodysplastic Syndrome;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Acute Leukemia;   Multiple Myeloma
    Interventions:   Biological: Rituximab;   Drug: Conditioning Chemotherapy;   Drug: TMS;   Drug: FLAG;   Drug: EPOCH-F;   Procedure: Hematopoietic Stem Cell Transplant;   Drug: Palifermin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Kidney Failure, Chronic;   Renal Insufficiency
    Interventions:   Drug: Belatacept;   Drug: ATG;   Drug: Rituximab;   Radiation: Total Body Irradiation;   Radiation: Thymic Irradiation;   Procedure: Combined Bone Marrow/Kidney Transplantation
    Sponsor:   Massachusetts General Hospital
    Recruiting

  • Conditions:   Kidney; Complications, Allograft;   Transplantation Infection
    Intervention:   Drug: Immunosuppressive Agents
    Sponsor:   Loma Linda University
    Recruiting

  • Conditions:   Graft Versus Host Disease;   Hematopoietic/Lymphoid Cancer
    Interventions:   Drug: fludarabine phosphate;   Drug: busulfan;   Drug: cyclophosphamide;   Procedure: allogeneic hematopoietic stem cell transplantation;   Drug: tacrolimus;   Drug: mycophenolate mofetil
    Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Primary Myelofibrosis;   Secondary Myelofibrosis
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Methotrexate;   Drug: Momelotinib;   Drug: Mycophenolate Mofetil;   Drug: Pacritinib;   Drug: Ruxolitinib;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Transplant; Failure, Kidney;   EBV
    Interventions:   Drug: belatacept;   Drug: Tacrolimus;   Drug: MPA
    Sponsors:   Lorenzo Gallon;   Bristol-Myers Squibb
    Recruiting

  • Conditions:   Severe Aplastic Anemia;   Bone Marrow Failure Syndromes
    Interventions:   Procedure: Bone marrow transplant;   Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: TBI;   Drug: Mesna;   Drug: Tacrolimus;   Drug: Mycophenolic acid mofetil
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Biphenotypic Leukemia;   Acute Leukemia of Ambiguous Lineage;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Allogeneic Hematopoietic Stem Cell Transplantation Recipient;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Donor;   Lymphoblastic Lymphoma;   Myelodysplastic Syndrome With Excess Blasts;   Myelodysplastic Syndrome With Excess Blasts-1;   Myelodysplastic Syndrome With Excess Blasts-2;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Refractory Acute Lymphoblastic Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Thiotepa;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Condition:   Liver Transplantation
    Interventions:   Biological: Anti-Thymocyte Globulin - Rabbit;   Biological: darTreg Infusion;   Drug: Everolimus;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Prednisone;   Drug: Acetaminophen;   Drug: Diphenhydramine;   Drug: Anti-Infective Prophylaxis;   Procedure: Leukapheresis;   Procedure: Blood draws;   Procedure: Liver biopsies;   Procedure: Liver transplantation
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  • Conditions:   Leukemia;   MDS;   Myelofibrosis;   Lymphoma
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Mesna;   Radiation: Total Body Irradiation;   Other: Hematopoietic stem cell infusion;   Drug: Tacrolimus;   Drug: Mycophenolate;   Drug: G-CSF
    Sponsor:   Rafic Farah, MD
    Recruiting

  • Conditions:   Multiple Myeloma;   Amyloidosis
    Interventions:   Drug: Tacrolimus;   Drug: Anti-thymocyte globulin;   Procedure: Kidney transplant;   Drug: Bone marrow transplant from a related donor;   Radiation: Total body irradiation 400 centigray (200 cGy X 2)
    Sponsor:   Massachusetts General Hospital
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Hematologic Malignancies;   Acute Lymphocytic Leukemia;   Non Hodgkin Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndrome;   Chronic Lymphocytic Leukemia;   Chronic Myeloid Leukemia;   Myelofibrosis;   Myeloproliferative Syndrome
    Interventions:   Radiation: total marrow irradiation;   Drug: fludarabine phosphate;   Drug: busulfan;   Procedure: myeloid progenitor cell transplantation;   Biological: anti-thymocyte globulin;   Drug: tacrolimus;   Drug: methotrexate;   Other: laboratory biomarker analysis
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Radiation: radiation therapy;   Drug: cyclophosphamide;   Biological: anti-thymocyte globulin;   Drug: tacrolimus;   Drug: methotrexate;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis
    Sponsor:   Ohio State University Comprehensive Cancer Center
    Recruiting

  • Condition:   Carcinoma, Hepatocellular
    Interventions:   Drug: Everolimus;   Drug: Tacrolimus;   Drug: Myfortic;   Drug: CellCept;   Drug: Imuran
    Sponsor:   Baylor Research Institute
    Recruiting

  • Conditions:   Chronic Myeloid Leukemia (CML);   Acute Myelogenous Leukemia (AML);   Myelodysplastic Syndrome (MDS);   Juvenile Myelomonocytic Leukemia (JMML);   Acute Lymphoblastic Leukemia (ALL);   Lymphoma (Hodgkin's and Non-Hodgkin's)
    Interventions:   Device: CliniMACS CD34+ Reagent System;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Alemtuzumab;   Drug: Tacrolimus;   Drug: Melphalan;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Methylprednisolone
    Sponsor:   Diane George, MD
    Recruiting

  • Condition:   Orthotopic Liver Transplant
    Interventions:   Drug: Everolimus;   Drug: Standard Tacrolimus
    Sponsor:   Tomoaki Kato
    Recruiting

  • Conditions:   Chronic Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Acute Biphenotypic Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Hodgkins Disease;   Chronic Lymphocytic Leukemia;   Multiple Myeloma
    Interventions:   Drug: tacrolimus;   Drug: methotrexate;   Drug: Mycophenolate mofetil;   Drug: Methotrexate (low dose)
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Leukemia;   Myeloproliferative Diseases
    Interventions:   Drug: Melphalan;   Drug: Fludarabine;   Procedure: Expanded NK Cell Infusion;   Procedure: Bone Marrow Transplant;   Drug: Mesna;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: G-CSF;   Radiation: Total Body Irradiation (TBI)
    Sponsors:   M.D. Anderson Cancer Center;   Cancer Prevention Research Institute of Texas
    Recruiting

  • Conditions:   Facial Injuries;   Traumatic Wounds and Injuries;   Craniofacial Injuries;   Craniofacial Defects
    Intervention:   Drug: Bone marrow cell-based therapy & 1-drug immunosuppression.
    Sponsor:   Johns Hopkins University
    Recruiting

  • Conditions:   Delayed Graft Function;   Kidney Transplant
    Interventions:   Drug: Belatacept;   Drug: Calcineurin Inhibitor
    Sponsors:   Nair, Vinay, D.O.;   Icahn School of Medicine at Mount Sinai;   Bristol-Myers Squibb
    Recruiting

  • Condition:   Leukemia
    Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Procedure: Alloreactive NK infusion;   Drug: Interleukin-2;   Procedure: Stem Cell Infusion;   Drug: G-CSF;   Drug: Tacrolimus;   Drug: Methotrexate
    Sponsors:   M.D. Anderson Cancer Center;   Cancer Prevention Research Institute of Texas;   CML Program Project Grant
    Recruiting

  • Conditions:   Chronic Myelogenous Leukemia (CML);   Acute Myelogenous Leukemia (AML);   Myelodysplastic Syndrome;   Multiple Myeloma;   Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia (CLL);   Acute Lymphocytic Leukemia (ALL);   Severe Aplastic Anemia
    Intervention:   Genetic: umbilical cord blood (UCB)
    Sponsor:   West Virginia University
    Recruiting

  • Conditions:   Myelodysplastic Syndrome;   Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia
    Interventions:   Biological: GVAX;   Biological: Placebo Vaccine;   Procedure: Allogeneic Hematopoietic Stem Cell Transplant;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Tacrolimus;   Drug: Methotrexate
    Sponsors:   Dana-Farber Cancer Institute;   Massachusetts General Hospital;   Beth Israel Deaconess Medical Center
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Juvenile Myelomonocytic Leukemia;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: Fludarabine phosphate;   Drug: Thiotepa;   Radiation: Total body irradiation;   Biological: Therapeutic allogeneic lymphocytes;   Drug: Cyclophosphamide;   Procedure: Allogeneic hematopoietic stem cell transplantation (HSCT);   Procedure: Peripheral blood stem cell transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Condition:   Lymphoma
    Interventions:   Drug: Gemcitabine;   Drug: Clofarabine;   Drug: Busulfan;   Procedure: Stem Cell Infusion;   Drug: Anti-Thymocyte Globulin;   Drug: Rituximab;   Drug: Filgrastim;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: Allopurinol;   Drug: Keppra;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Biological: Allogeneic hematopoietic stem cell transplant;   Biological: Filgrastim;   Biological: antithymocyte globulin
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Lymphoma;   Leukemia
    Interventions:   Drug: CMC-544;   Drug: Fludarabine;   Drug: Bendamustine;   Drug: Rituximab;   Procedure: Allogeneic Stem Cell Transplantation;   Drug: Thymoglobulin;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: G-CSF
    Sponsors:   M.D. Anderson Cancer Center;   Pfizer
    Recruiting

  • Conditions:   Leukemia;   Chronic Lymphocytic Leukemia
    Interventions:   Drug: Lenalidomide;   Drug: Fludarabine monophosphate;   Drug: Melphalan;   Procedure: NK Infusion;   Procedure: CB Infusion;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Rituximab;   Drug: Cyclophosphamide
    Sponsors:   M.D. Anderson Cancer Center;   Celgene;   American Cancer Society, Inc.;   CLL Global Research Foundation
    Recruiting

  • Condition:   Diabetes Mellitus, Type 1
    Interventions:   Biological: Allogenic islet cells (human, U. Chicago);   Procedure: Intraportal infusion of islet cells
    Sponsor:   University of Chicago
    Recruiting

  • Conditions:   Amputation, Traumatic;   Wounds and Injuries;   Hand Injuries
    Interventions:   Procedure: Deceased donor hand transplantation;   Drug: Bone marrow cell-based therapy & single-drug immunosuppression.
    Sponsors:   Johns Hopkins University;   Armed Forces Institute of Regenerative Medicine;   U.S. Army Medical Research Acquisition Activity
    Recruiting

  • Conditions:   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Aplastic Anemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Myelodysplastic Syndromes;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Mastocytosis;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Polycythemia Vera;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia;   Refractory Anemia With Ringed Sideroblasts;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Radiation: Total Body Irradiation (TBI);   Biological: Donor Lymphocyte Infusion (DLI);   Drug: Cyclophosphamide (CY);   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Device: Allogeneic hematopoietic stem cell transplantation;   Procedure: Peripheral blood stem cell transplantation (PBSCT)
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Condition:   Hematological Malignancies
    Interventions:   Radiation: Total Body Irradiation;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Fludarabine;   Drug: Busulfan;   Genetic: Hematopoietic stem cell transplantation
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Complete DiGeorge Anomaly;   DiGeorge Syndrome;   DiGeorge Anomaly;   Complete DiGeorge Syndrome
    Interventions:   Biological: Thymus Tissue for Transplantation;   Procedure: Blood Draw;   Drug: Rabbit anti-thymocyte globulin;   Drug: Cyclosporine;   Drug: Tacrolimus;   Drug: Methylprednisolone or Prednisolone;   Drug: Basiliximab;   Drug: Mycophenolate mofetil
    Sponsors:   M. Louise Markert;   National Institutes of Health (NIH);   National Institute of Allergy and Infectious Diseases (NIAID);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Enzyvant Therapeutics GmbH
    Available

  • Condition:   Hematologic Malignancies
    Interventions:   Drug: Fludarabine, Cytoxan, TBI, Sirolimus + MMF;   Drug: Fludarabine, Cytoxan, TBI, Tacrolimus + MMF
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Erythroid Leukemia in Remission;   Acute Leukemia in Remission;   Acute Megakaryoblastic Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Acute Myeloid Leukemia With FLT3/ITD Mutation;   Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2) or t(3;3) (q21.3;q26.2); GATA2, MECOM;   Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM;   Acute Myeloid Leukemia With Multilineage Dysplasia;   Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   B Acute Lymphoblastic Leukemia With t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1);   B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Complete Remission;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   Myelodysplastic Syndrome;   Recurrent Anaplastic Large Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   Secondary Acute Myeloid Leukemia;   T Lymphoblastic Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   B-Cell Prolymphocytic Leukemia;   Hypodiploidy;   Loss of Chromosome 17p;   Plasma Cell Leukemia;   Progression of Multiple Myeloma or Plasma Cell Leukemia;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Childhood Hodgkin Lymphoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Non-Hodgkin Lymphoma;   Refractory Plasma Cell Myeloma;   Refractory Small Lymphocytic Lymphoma;   t(14;16);   t(4;14);   T-Cell Prolymphocytic Leukemia;   Waldenstrom Macroglobulinemia
    Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Procedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Hematopoietic Cell Transplantation Recipient;   Non-Malignant
    Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Biological: Anti-Thymocyte Globulin;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Drug: Treosulfan;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   medac GmbH;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Metabolic Disorders;   Hematologic, Immune, or Bone Marrow Disorders;   Hemoglobinopathies;   Non-malignant Disorders
    Interventions:   Drug: Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan;   Drug: Transplant conditioning regimen of hydroxyurea, campath, fludarabine, thiotepa, & melphalan
    Sponsors:   Washington University School of Medicine;   St. Louis Children's Hospital
    Recruiting

  • Condition:   Lymphoma, Non-Hodgkin
    Interventions:   Procedure: Stem cell infusion;   Procedure: TLI;   Drug: Anti-thymocyte globulin;   Drug: Solumedrol;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Condition:   Atopic Dermatitis
    Intervention:   Drug: Pimecrolimus
    Sponsors:   Valeant Pharmaceuticals International, Inc.;   Clinical Research Computing Unit (University of Pennsylvania)
    Recruiting

  • Conditions:   Immunodeficiency Syndrome;   Non-Cancer Diagnosis;   Severe Aplastic Anemia
    Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Sirolimus;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting